» Articles » PMID: 35400820

Effect of Tocotrienol on the Primary Progression of Nonalcoholic Steatohepatitis in a Mouse Model

Overview
Specialty Biochemistry
Date 2022 Apr 11
PMID 35400820
Authors
Affiliations
Soon will be listed here.
Abstract

Tocotrienol (T3), a vitamin E (Vit E) isoform, is known to have both biological and antioxidant effects. Although alpha-tocopherol (α-Toc), another isoform of Vit E is suggested to be a useful treatment against nonalcoholic steatohepatitis (NASH), the effect of T3 on NASH is unclear. This study aimed to comparatively evaluate the effects of T3 and α-Toc on NASH in the early stage of NASH progression, using a recently established NASH mouse model induced by a choline-deficient l-amino acid-defined high-fat diet (CDAHFD). Six-week-old male mice were divided into four groups ( = 6 per group) and fed the CDAHFD for 1 week. The first group was given no other treatment (Pre). The other three groups continued the CDAHFD plus daily oral administration of Vit E-free corn oil (Control), corn oil containing α-Toc, or corn oil containing T3 for additional 2 weeks. Neither Vit E treatment changed the histologic features of NASH, but T3 significantly reduced the mRNA expression of several genes related to inflammation and fibrosis and α-Toc did not. These results suggested that oral T3 treatment was more effective than α-Toc at suppressing hepatic inflammation and fibrosis in the early stage of NASH progression in CDAHFD model mice.

Citing Articles

Short-term intake of delta-tocotrienol on lipid profiles in healthy subjects.

Serizawa N, Ninomiya Y, Shinagawa A, Minematsu A, Miyakoshi Y, Yano T J Clin Biochem Nutr. 2025; 76(1):3-7.

PMID: 39896164 PMC: 11782774. DOI: 10.3164/jcbn.24-124.


Anti-fibrotic effect of tocotrienols for bladder dysfunction due to partial bladder outlet obstruction.

Iguchi N, Donmez M, Malykhina A, Wilcox D Investig Clin Urol. 2023; 64(2):189-196.

PMID: 36882179 PMC: 9995959. DOI: 10.4111/icu.20220328.


Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review.

Chin K, Ekeuku S, Chew D, Trias A Nutrients. 2023; 15(4).

PMID: 36839192 PMC: 9965814. DOI: 10.3390/nu15040834.

References
1.
Perumpail B, Li A, John N, Sallam S, Shah N, Kwong W . The Role of Vitamin E in the Treatment of NAFLD. Diseases. 2018; 6(4). PMC: 6313719. DOI: 10.3390/diseases6040086. View

2.
Yu H, Fellows A, Foote K, Yang Z, Figg N, Littlewood T . FOXO3a (Forkhead Transcription Factor O Subfamily Member 3a) Links Vascular Smooth Muscle Cell Apoptosis, Matrix Breakdown, Atherosclerosis, and Vascular Remodeling Through a Novel Pathway Involving MMP13 (Matrix Metalloproteinase 13). Arterioscler Thromb Vasc Biol. 2018; 38(3):555-565. PMC: 5828387. DOI: 10.1161/ATVBAHA.117.310502. View

3.
Peh H, Tan W, Liao W, Wong W . Vitamin E therapy beyond cancer: Tocopherol versus tocotrienol. Pharmacol Ther. 2015; 162:152-69. DOI: 10.1016/j.pharmthera.2015.12.003. View

4.
Kim Y, Natarajan S, Chung S . Gamma-Tocotrienol Attenuates the Hepatic Inflammation and Fibrosis by Suppressing Endoplasmic Reticulum Stress in Mice. Mol Nutr Food Res. 2018; 62(21):e1800519. DOI: 10.1002/mnfr.201800519. View

5.
Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View